Resistance to apoptosis is a recurrent theme in colon cancer. We have shown previously that the 7-transmembrane spanning receptor OX1R for orexins promote robust apoptosis in the human colon cancer cell line HT29 through an entirely novel mechanism involving phosphorylation of tyrosine-based motifs in OX1R. Here, we investigated the status of OX1R in a large series of human colorectal tumors and hepatic metastases. All primary colorectal tumors regardless of their localization and Dukes' stages and all hepatic metastases tested expressed OX1R mRNA and/or protein. In sharp contrast, adjacent normal colonocytes or hepatocytes as well as control normal tissues were negative. Next, we showed that 9 human colon cancer cell lines established from primary tumors or metastases expressed OX1R mRNA and underwent important apoptosis upon orexin-A challenge. Most interestingly, orexin-A also promoted robust apoptosis in cells which are resistant to the most commonly used drug in colon cancer chemotherapy, 5-fluorouracil. When human colon cancer cells were xenografted in nude mice, orexin-A administered at day 0 strongly slowed the tumor growth and even reversed the development of established tumors when administered 7 days after cell inoculation. Orexin-A also acts by promoting tumor apoptosis in vivo since caspase-3 is activated in tumors upon orexin treatment of nude mice. These findings support that OX1R is an Achilles heel of colon cancers, even after metastasis or chemoresistance. They suggest that OX1R agonists might be novel candidates for colon cancer therapy.
Introduction
Colon cancer is a leading cause of cancer mortality in many countries (1) . Molecular genetic studies have identified key genes whose mutations or altered expression can cause colon cancer (2) . Many observations also indicated that colon cancer growth is under the control of a variety of peptide growth factors (3) acting at tyrosine kinase receptors or G protein-coupled receptors. Among those receptors, epidermal growth factor receptor (EGFR) is prominent in colon cancers (4) due to its autoactivity and also because it can be transactivated by G protein-coupled receptors (5) . It is a therapeutic target since antibodies directed against EGFR have shown efficacy in colorectal cancer (4) .
Much less is known about receptors and/or peptides that inhibit growth and/ or promote apoptosis of colon cancer cells. Some years ago we reasoned that besides growth factors or peptide hormones that promote colon cancer growth (3), we should be able to find natural peptides behaving as suppressors of colon cancer growth. We tested this hypothesis by screening the ability of a large series of peptide hormones and neuropeptides to inhibit the growth of the human colon cancer cell line HT29 cultured in the presence of fetal calf serum (6) . We made two hits with orexin-A and orexin-B which appear to be robust growth inhibitors (6) . Orexins do not alter cell cycle but promote strong apoptosis by inducing cytochrome c release from mitochondria to cytosol and activation of caspase-3 and caspase-7 (6).
Orexin-A and orexin-B (7), also named hypocretin-1 and hypocretin-2 (8), were discovered as hypothalamic peptides that are encoded in a preproorexin precursor.
The two peptides are present in hypothalamic neurons that regulate sleep, wakefullness, feeding, breathing, reward system or drug addiction (9) . Functions of orexins have been also described in a few peripheral tissues (10, 11) but expression of orexins at the periphery remains debatable (11) (12) (13) . Classically, the actions of orexins are mediated by two seven-pass transmembrane receptors OX1R and OX2R (7) the activation of which induces cellular calcium transients through Gq-dependent and -independent pathways (14) .
We showed that OX1R triggers apoptosis by an entirely novel mechanism (15, 16) which is not related to Gq-mediated phopholipase C activation and cellular calcium transients (13) . Orexins induce tyrosine phosphorylation of two tyrosinebased motifs in OX1R, ITIM and ITSM, resulting in the recruitment of the phosphotyrosine phosphatase SHP-2 the activation of which is responsible for mitochondrial apoptosis (15, 16) .
Given that i) failure of tumor cells to undergo apoptosis translates into tumor progression and chemotherapeutic resistance, ii) apoptosis emerges as a potential target for cancer treatment (17, 18) , it was important to determine the status of orexin receptors and orexin-induced apoptosis in colon cancer. In the present work, we addressed this question by studying the expression of orexin receptors in a large series of primary colonic tumors and also in hepatic metastases. We also investigated the ability of orexins to promote apoptosis in a large panel of colon cancer cell lines. We show that the receptor OX1R is not present in normal colon or liver but is aberrantly expressed in all primary tumors and hepatic metastases tested.
Futhermore we demonstrate that orexins promote apoptosis in most of the colon cancer cell lines tested including in cells which are resistant to 5-fluorouracil, the most commonly used drug in colon cancer chemotherapy (4) . Finally, we showed that orexins strongly reduced the development of tumors in nude mice xenografted with human colon cancer cells. Since peripheral expression of orexins is debatable (13), we also studied the expression of the orexin precursor mRNA by RT-qPCR in primary 
Materials and Methods

Tissue collection
Thirty-eight archival specimens of formalin-fixed, paraffin-embedded human colonic carcinomas were selected to offer a sampling according to the severity of the disease and the different sites of the large intestine (see Table 1 ). Biopsy samples obtained during endoscopy of normal adults suffering from irritable bowel syndrome were also studied. Several frozen unfixed tissues were used for RT-qPCR : 10 colonic carcinoma, 5 non tumoral colon tissues, 10 hepatic metastasectomies and 7 non tumoral hepatic tissues. Tissues were used in accordance with the requirements of the Human Research Committee of Hospital Bichat, Paris. Hypothalamus cDNAs prepared from human normal brains were obtained from Clontech (St Quentin en Yvelyne, France).
Cell Lines culture
The human colon cancer cell lines were obtained from ATCC (Rockville, MD).
The cell lines were established from resected tumors (19, 20) as follows : HT29, SW480, SW48, Caco-2, LS174T and HCT116 from primary colorectal adenocarcinomas; T84 from lung metastases; SW620 from lymph node metastases;
Colo205 from ascite metastases and LoVo from left supraclavicular metastases. The HT29-FU cell line which resists to 1 µM 5-fluorouracil (5-FU) was obtained as described (21, 22 
Quantification of apoptotic cells by annexin V labelling
Apoptotic cells were determined using the Guava Nexin TM kit (Guava Technologies, Hayward, CA, USA) which discriminates between apoptotic and nonapoptotic cells as described (6) . Cells were incubated with fresh medium containing or not 1 µM orexin-A. After 48 h, apoptotic cell staining was analyzed with a Guava PCA system (15) . Results are expressed as the percentage of apoptotic Annexin V-PE positive cells and are the means of 3 independent analyses. .
RT-qPCR procedure
Tumorigenicity assay in nude mice
Exponentially 
Results
OX1R is aberrantly expressed in human colon tumors ex vivo.
We investigated OX1R expression in colonic adenocarcinomas versus normal colonic epithelium by immunohistochemistry. All the 38 tumors tested (Table 1) were immunoreactive for OX1R ( Figure 1 ). The immunostaining was specific since it disappeared after incubation of the OX1R antibody with its homologous immunogen peptide ( Figure 1 ) or when the primary antibody was omitted (not shown). On sections, 50 to 100% of cells were immunoreactive (Table 1 ). In contrast, normal proximal and distal mucosae of patients with irritable bowel syndrome, taken as controls, did not express OX1R ( Figure 1A ). This is in good agreement with RTqPCR experiments which also failed to detect any OX1R mRNA in the same tissue samples ( Table 2 ). The mean percentages of immunoreactive cells were similar in the proximal and distal colon i.e. 82 and 83%, respectively. In these two sites, there was no correlation between the numbers of cells showing OX1R expression and the severity of the tumor. The same holds true for the intensity of immunostaining which was also independent of the severity of the tumor, variable from one tumor to another and between cells within a tumor. Immunostaining was observed in neoplastic glands whereas normal glands and still normal colonocytes remained negative ( Figure 1C , D). OX2R mRNA was not detectable by RT-qPCR in any colon cancer tested ( Table   2 ). We conclude that OX1R is aberrantly expressed in epithelial cells during colon carcinogenesis.
The immunoexpression of OX1R in colon cancer cells was detected predominantly intracellularly in cytoplasm and/or nucleus but also at the plasma membrane with a variability depending on the tumor (Figure 1 ). For the whole of colonic cancers, the immunoreactivity predominated for 58% of them in the (13) is activation at the plasma membrane by external ligands, we further explored the cellular distribution of OX1R in HT29 cells in which external orexins promote apoptosis (6) . When immunostaining was performed on HT29 cell pellets under the same procedure as that used for colon tumors, very similar data were obtained i.e. labelling of intracellular compartments and the plasma membrane ( Supplementary Fig.1 ).
Since orexins were previously claimed to be present in the gut (26) , though this view is now debatable (13), we tested the possible presence of the orexin precursor mRNA in 10 colonic tumors. No orexin precursor transcript could be detected in any colon tumor (Table 2 ) under conditions in which specific amplification products were detected in human hypothalamus taken as a control tissue where orexins are mainly produced (7, 8) . These data indicate that colon tumors express the orexin receptor OX1R but not the orexin peptides.
OX1R is aberrantly expressed in human hepatic metastases from colorectal cancers ex vivo
Next, we raised the question of whether OX1R present in primary colon tumors were still expressed after migration in their main site of metastasis, e.g. the liver. A collection of 10 human hepatic metastases was investigated for the expression of OX1R transcripts using RT-qPCR. Seven samples of normal liver tissue which are adjacent to metastases were used as controls. As shown in the Figure 2A qPCR experiments failed to detect any OX1R mRNA in normal liver samples ( Figure   2A ). The expression of OX1R mRNA was similar in liver metastases and primary colon tumors ( Figure 2 and Table 2 ). We confirmed these data by investigating OX1R expression by immunohistochemistry in hepatic metastases ( Figure 2B ). All metastatic tumors studied expressed OX1R whereas adjacent normal hepatocytes remained negative. It is also worth noting that no orexin precursor mRNA could be detected by RT-qPCR in human liver ( Table 2 ). Altogether these data indicated that after colon cancer cell migration to the liver, metastatic nests still express OX1R.
OX1R mRNA expression and orexin-induced apoptosis in human colon cancer cell lines including 5-FU-resistant cells
A large collection of colon cancer cell lines was investigated for the expression of OX1R transcripts using RT-qPCR. Expression of OX1R mRNA could be detected in all colon cancer cell lines but one, i.e. HCT116 ( Figure 3A) . No mRNA for the other orexin receptor subtype OX2R could be detected in any cell line tested (not shown).
Orexin-A (1 µM) induced apoptosis ( Figure 3B ) and subsequent reduction in cell number ( Supplementary Fig. 2 ) in all colon cancer cell lines tested but one, i.e.
HCT116. Similar results were obtained with orexin-B (data not shown). It is worth
noting that these effects were observed in culture medium containing FCS which promotes robust cell growth. The extents of apoptosis were variable from one cell line to another (Figure 3 ). Quite interestingly, they are strongly correlated with the amounts of OX1R mRNA detected in the various cell lines ( Figure 3C ). Altogether, these data indicated that functional OX1 receptors that are able to promote apoptosis are readily expressed in most of the colon cancer cell lines. 
The most commonly used drug in colon cancer chemotherapy, 5-fluorouracil Two other human colon cancer cell lines which expressed or not OX1R (Fig. 3), were also xenografted in nude mice e.g. HT29 and HCT116, respectively.
Treatment of mice developing HT29 tumors with orexin-A resulted in drastic reduction
of tumor volume (Fig. 5C ) whereas no effect could be observed with HCT116 tumors (Fig. 5D ). 
Discussion
In this work, we showed that ectopic expression of the orexin receptor OX1R is a very frequent event in colon tumorigenesis regardless of the location of primary cancer in proximal or distal large intestine and also of their severity from Duke's A to Duke's C grade. Indeed, OX1R is expressed in all 38 colorectal tumors tested but not in normal glands, still normal colonocytes and control non tumoral colonic mucosa of patients with irritable bowel syndrome. This aberrant expression is maintained after metastatic migration of colon cancer cells to the liver which does not itself express OX1R in healthy conditions. We also showed that activation of OX1R by exogenous OX1Rs are expressed in all hepatic metastases of colorectal cancer ( Figure 2) and in colon cancer cell lines established from lymph nodes, ascite or lung metastases ( Figure 3A) . This is an important point for two reasons: i) the status of a given receptor may be different in primary tumors and metastases. For example, the EGFR status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites (29) . A loss of EGFR expression was observed in a significant number of lymph node and liver metastases (29, 30) , an event which has evident implication for treatment with EGFR-targeted antibodies (29) . The status of OX1R appears to be similar in primary colorectal tumors and liver metastases. This is crucial if we consider that OX1R could represent a new target in colon cancer therapy or for metastases imaging. Indeed, the possibility to use OX1R-targeted agonists in order to induce apoptosis of cancer cells is more relevant in metastases, including micrometastases, than in the primary tumor which can be resected; ii) the liver is the main site of colorectal cancer metastasis. The status of OX1R in hepatic metastases appears to be suitable for imaging of micrometastases. The high affinity of OX1R for orexins makes this target convenient for radioisotopic imaging with 111 In-labeled OX1R agonists as described previously for in vivo imaging of tumors with radiolabeled peptides (31) . For imaging, it is also crucial that normal liver cells do not express OX1R (Figure 2) . In that respect, OX1R appears to be much more interesting for imaging than vasoactive intestinal peptide (VIP) receptors (32) which are not only expressed in colon cancers (33) but also highly expressed throughout the normal human gut (34, 35) and liver (36) .
The current view of the 7-pass transmembrane OX1R mediating apoptosis follows a mechanism that involves orexin binding at the plasma membrane triggering tyrosine phosphorylation of two tyrosine-based motifs ITIM (15) and ITSM (16) 
In vivo experiments with human colon cancer cells xenografted in nude mice
show that orexin-A is very efficient in slowing the tumor growth. It works at dose as low as 0.112 µmoles/kg and reaches a maximal effect at 1.12 µmoles/Kg. Not only orexin-A is able to drastically slow tumor growth when administered at the same time as cell inoculation (day 0), but most interestingly it also reverses very rapidly the growth of already established tumors (see Fig. 5B ). It has been shown previously that orexins inhibit cultured colon cancer cell growth by inducing apoptosis without altering cell cycle (6) . It is likely that orexins also reduced tumor growth in vivo by promoting apoptosis since we showed by immunostaining (see supplementary Fig. 4) that caspase-3 is activated in tumors upon orexin treatment.
The orexin receptor OX1R in colon cancer might be considered as a new type of gene in cancer since it is aberrantly expressed as a functional protein whose function, when activated by an agonist, is to promote apoptosis of the cancer cell.
The colon cancer cells unexpectedly provide a new gate to promote their death by apoptosis which was not present in the normal colonocyte from which they derive. In T1   T2   T3   T4   T5   T6   T7   T8   T9   T10 
